GlassScriptPhysician profile
Lisa Capaldini
NPI 1841249240
$433,727.02
in general payments reported to CMS, 2019-2025
15 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $55K · 2021: $23K · 2022: $37K · 2023: $44K · 2024: $92K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150K · Travel and Lodging: $22K · Consulting Fee: $18K · Food and Beverage: $10K · Education: $39.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,385.00 |
| Travel and Lodging | $22,292.16 |
| Consulting Fee | $18,485.83 |
| Food and Beverage | $10,179.01 |
| Education | $39.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $337,816.43 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $86,207.69 | 2019-2025 | Biktarvy, Descovy |
| Merck Sharp & Dohme LLC | $5,988.91 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Theratechnologies INC. | $1,082.04 | 2021-2023 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $731.62 | 2019-2023 | Symtuza |
| Roche Diagnostics Corporation | $436.32 | 2019 | |
| Axsome Therapeutics, INC. | $351.07 | 2023-2025 | Auvelity |
| Amarin Pharma, INC. | $314.12 | 2019-2020 | |
| Janssen Products, LP | $308.99 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $216.11 | 2020-2023 | Symtuza |
| Novo Nordisk INC | $109.28 | 2024-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $66.86 | 2020-2021 | |
| Abbvie INC. | $60.09 | 2021 | |
| Antares Pharma, INC. | $19.36 | 2021 | |
| Allergan, INC. | $18.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Capaldini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.